Malignant B cells at the helm in follicular lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2641-2642

  Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; LYMPHOCYTE ANTIGEN RECEPTOR; MACROPHAGE DERIVED CHEMOKINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; CYTOKINE RELEASE; DENDRITIC CELL; EDITORIAL; EFFECTOR CELL; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; LYMPH NODE; MONOCYTE; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, FOLLICULAR;

EID: 84890451511     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.2165     Document Type: Editorial

References (13)

1. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
2. Yang ZZ, Novak AJ, Ziesmer SC, et al: CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 110:2537-2544, 2007
3. Andorsky DJ, Yamada RE, Said J, et al: Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 17:4232-4244, 2011
4. Wilcox RA, Feldman AL, Wada DA, et al: B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114:2149- 2158, 2009
5. Yang ZZ, Novak AJ, Stenson MJ, et al: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646, 2006
6. Yang ZZ, Novak AJ, Ziesmer SC, et al: Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 66:10145-10152, 2006
7. Ansell SM, Maurer MJ, Ziesmer SC, et al: Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 87:865-869, 2012
8. Yang ZZ, Grote DM, Ziesmer SC, et al: IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122:1271-1282, 2012
9. Yang ZZ, Novak AJ, Ziesmer SC, et al: Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 69:5522-5530, 2009
10. Kiaii S, Clear JC, Ramsay AG, et al: Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation. J Clin Oncol 31:2654-2661, 2013
11. Curran KJ, Pegram HJ, Brentjens RJ: Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med 14:405-415, 2012
12. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
13. Davila ML, Brentjens R, Wang X, et al: How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 1:1577-1583, 2012